Structures of Hsp90 alpha and Hsp90 beta bound to a purine-scaffold inhibitor reveal an exploitable residue for drug selectivity.
Huck, J.D., Que, N.L.S., Sharma, S., Taldone, T., Chiosis, G., Gewirth, D.T.(2019) Proteins 87: 869-877
- PubMed: 31141217 
- DOI: https://doi.org/10.1002/prot.25750
- Primary Citation of Related Structures:  
6N8W, 6N8X, 6N8Y, 6OLX - PubMed Abstract: 
Hsp90α and Hsp90β are implicated in a number of cancers and neurodegenerative disorders but the lack of selective pharmacological probes confounds efforts to identify their individual roles. Here, we analyzed the binding of an Hsp90α-selective PU compound, PU-11-trans, to the two cytosolic paralogs ...